# RHEUMATOLOGY

## Original article

# Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries

Bente Glintborg [1,2,*], Daniela Di Giuseppe [3,*], Johan K. Wallman [4], Sella A. Provan [5], Dan Nordström[6], Anna-Mari Hokkanen [7], Jenny Österlund[8], Eirik Kristianslund[5], Tore K. Kvien[5], Bjorn Gudbjornsson[9], Merete Lund Hetland [1,2], Brigitte Michelsen[5,10], Lennart Jacobsson [11], Johan Askling[3] and Ulf Lindström [11]

## Abstract

**Objectives.** The positioning of secukinumab in the treatment of axial SpA (axSpA) and PsA is debated, partly due to a limited understanding of the comparative safety of the available treatments. We aimed to assess the risk of the key safety outcome infections during treatment with secukinumab and TNF inhibitors (TNFi).

**Methods.** Patients with SpA and PsA starting secukinumab or TNFi year 2015 through 2018 were identified in four Nordic rheumatology registers. The first hospitalized infection during the first year of treatment was identified through linkage to national registers. Incidence rates (IRs) with 95% CIs per 100 patient-years were calculated. Adjusted hazard ratios were estimated through Cox regression, with secukinumab as the reference. Several sensitivity analyses were performed to investigate confounding by indication.

**Results.** Among 7708 patients with SpA and 5760 patients with PsA, we identified 16 229 treatment courses of TNFi (53% bionaïve) and 1948 with secukinumab (11% bionaïve). For secukinumab, the first-year risk of hospitalized infection was 3.5% (IR 5.0; 3.9–6.3), compared with 1.7% (IR 2.3; 1.7–3.0) during 3201 courses with adalimumab, with the IRs for other TNFi lying in between these values. The adjusted HR for adalimumab, compared with secukinumab, was 0.58 (0.39–0.85). In sensitivity analyses, the difference from secukinumab was somewhat attenuated and in some analyses no longer statistically significant.

**Conclusion.** When used according to clinical practice in the Nordic countries, the observed first-year absolute risk of hospitalized infection was doubled for secukinumab compared with adalimumab. This excess risk seemed largely explained by confounding by indication.

**Key words:** spondylarthropathies, biologic therapies, immunosuppressants, DMARDs, epidemiology

CLINICAL SCIENCE

[1]DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital, Rigshospitalet, Glostrup, [2]Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, [3]Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, [4]Department of Clinical Sciences Lund, Rheumatology, Lund University, Skane University Hospital, Lund, Sweden, [5]Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway, [6]Department of Medicine and Rheumatology, Helsinki University and Helsinki University Hospital, Helsinki, [7]Päijät-Häme Central Hospital, Lahti, [8]Division of Medicine, Helsinki University, Helsinki, Finland, [9]Centre for Rheumatology Research, Landspitali University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, [10]Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway and [11]Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Correspondence to: Ulf Lindström, Department of Rheumatology and Inflammation Research, University of Gothenburg, Box 115, Gothenburg, Sweden. E-mail: ulf.lindstrom@gu.se

*Bente Glintborg and Daniela Di Giuseppe contributed equally to this study.

> **Rheumatology key messages**
> - In clinical practice, secukinumab was mainly used in biologic DMARD–experienced patients.
> - In this setting, secukinumab was associated with higher absolute risk of hospitalized infections than adalimumab.
> - The crude excess risk seemed largely explained by more frequent secukinumab use in difficult-to-treat patients.

## Introduction

The IL 17-inhibitors (IL17i) secukinumab and ixekizumab are both approved for use in axial SpA (axSpA) and PsA. The EULAR recommendations for PsA currently place IL17 inhibitors (IL17i) alongside TNF-α inhibitors (TNFi) and ustekinumab as possible first-line biologic or targeted synthetic DMARDs (b/tsDMARDs) [1]. In contrast, the ACR guidelines for PsA and for axSpA, as well as the EULAR recommendations for axSpA, position TNFi before IL17i [2–4].

Since the effectiveness of IL17i and TNFi appears to be similar for the arthritis component of PsA and for the axial symptoms of axSpA [5–8], the choice of mode of action (MOA) may depend on other factors, such as disease features, comorbidities, safety concerns, or costs. Comparative studies of risk of infections during treatment with various types of biologic DMARDs (bDMARDs) have primarily been performed in RA, where they have revealed differences in the safety profiles that may have a direct impact on the choice of treatment for individual patients [9, 10]. For IL17i, safety data informing such choices are considerably sparser.

Considering the different MOAs of TNFi and IL17i, it could be expected that both the overall risk of serious infections and of specific types of infections (e.g. tuberculosis and candida) may differ between the drug classes [11–14]. However, randomized controlled trials (RCTs) comparing efficacy of IL17i and TNFi in PsA and psoriasis have reported similar overall rates of infections [7, 8, 15, 16]. Pooled analyses from a large number of RCTs on secukinumab suggest a rate of serious infections of 1.9 per 100 patient-years for PsA and 1.2 for AS [17], while similar analyses for adalimumab have indicated a rate of 2.8 for PsA and 1.4 for AS [18]. Although patients included in RCTs may not represent patients treated in routine care [19, 20], one large observational study comparing the occurrence of serious infections between PsA and psoriasis in patients treated with various DMARDs also reported similar rates for TNFi and IL17i [21].

The main objective of this study was to compare the overall risk of hospitalized infections during the first year of treatment with secukinumab and the various TNFi, in patients with SpA and PsA. As a secondary aim, we compared the risk of specific types of infections of particular interest (both hospitalized infections and infections in outpatient specialized care), namely pneumonia, urinary tract infections, tuberculosis, fungal infections, erysipelas, and herpes zoster.

## Methods

### Study design

This is an observational study based on prospectively collected register data.

### Setting and data sources

Patients were identified in rheumatology registers in four of the Nordic countries: Denmark (DANBIO), Finland (ROB-FIN), Norway (NOR-DMARD) and Sweden (ARTIS/SRQ) [22]. From these registers, data on b/tsDMARD treatment courses and disease-specific measures were retrieved and linked to national registers to collect data on comorbidities and infections prior to treatment start and during treatment [23]. The linked data were available throughout years 2010–2018 for all countries apart from Denmark (data available until 31 July 2018). All ICD-codes used to identify patients, comorbidities and outcomes are presented in Supplementary Table S1, available at *Rheumatology* online.

### Patients and treatments

All patients in the rheumatology registers with SpA or PsA (registered either as clinical diagnoses or as ICD-codes), starting secukinumab or a TNFi (adalimumab, certolizumab pegol, etanercept, golimumab or infliximab) in 2015 through 2018 were included. Each patient contributed with all different consecutive b/tsDMARD courses they started during this period, but switching between an originator and the corresponding biosimilar was disregarded, as were restarts following shorter interruptions of treatment (<60 days, e.g. due to surgery).

Clinical data at each treatment initiation were identified in the rheumatology registers as at the registered visit closest to the treatment start-date, within a window of –30 to +14 days. Previous comorbidities, registered within 5 years before treatment start, were identified in national registries for the following conditions: malignancy, diabetes, chronic pulmonary disease, congestive heart disease, myocardial infarction, kidney failure, and hip/knee prosthesis. From this a 'comorbidity score' (0, 1, 2+) was calculated for each patient by adding together the number of different comorbidities.

### Follow-up

Patients were followed from the start-date of each treatment course (=baseline), until the first of the following: 12 months thereafter, 31 December 2018 (31 July 2018

for Denmark) or 90 days after treatment discontinuation. The follow-up was extended to 90 days after discontinuation in order to include infectious episodes occurring during treatment washout, but if another b/tsDMARD treatment was started during this period, the follow-up for the previous course was censored at the start of the subsequent treatment.

### Outcomes

The main outcome was the first hospital discharge during follow-up listing an infection as a main or contributory discharge diagnosis (i.e. a hospitalized infection). The secondary outcome was the first infection registered during follow-up at hospital discharge or in specialized outpatient care (=hospitalized infections and infections in outpatient specialized care) of the following types: tuberculosis, pneumonia, herpes zoster, fungal infections, urinary tract infection, and erysipelas.

### Statistics

Absolute risks of a first infection during treatment were described through cumulative incidence curves and percentages. We also calculated incidence rates (IR), and their 95% CIs, per 100 patient-years.

Hazard ratios (HRs) for a first infection were calculated through Cox regression in two models, comparing all TNFi with secukinumab as the reference. It was decided a priori to focus on adalimumab as the main comparator, since adalimumab is commonly used as an active comparator in clinical trials, and as a direct comparator in head-to-head studies. First, a basic model was used, adjusted only for sex and baseline age (continuous with a quadratic parameter). Second, a fully adjusted model was used, additionally adjusted for number of previous b/tsDMARDs (0, 1, 2, 3 and 4+) and the following baseline factors: disease duration (<1, 1–4, 4–10, >10 years), history of any registered infection (hospitalized infections and infections in outpatient specialized care) up to 5 years before treatment start (yes/no), the comorbidity score, concomitant use of conventional synthetic DMARDs (csDMARDs) (yes/no) and corticosteroids (yes/no), and disease characteristics: patient global visual analogue scale assessment of disease activity (VAS-global, 0–100 mm), HAQ, swollen joint count (0–28) and tender joint count (0–28) (all categorized according to quartiles and a fifth missing category). These disease characteristics were selected to capture disease severity with generic variables applicable in both SpA and PsA. The fully adjusted analysis also included country as strata. In the combined analyses of SpA and PsA, disease type (SpA or PsA) was included in the model as an additional covariate. Robust standard errors were used to adjust for multiple treatments per patient.

No IR or HR estimates were calculated for outcomes with fewer than 10 events in either of the exposure groups. Heterogeneity across the included countries was assessed though a random effects meta-analysis based

on the main adjusted Cox model, with SpA and PsA combined and comparing adalimumab with secukinumab. The main objective was assessed for SpA and PsA combined as well as stratified.

### Sensitivity analyses

In order to further explore the main outcome and to accommodate confounding by indication, four sensitivity analyses were performed based on the main outcome, also including a comparison between secukinumab and the combined TNFi cohort. First, only previously bionaïve patients were included. Second, since patients starting secukinumab had (on average) more previous b/tsDMARD treatments, we performed an analysis restricted to patients who were starting their second or more bDMARD treatment. In this analysis, all patients with a previous infection (hospitalized infections and infections in outpatient specialized care, up to 5 years prior to treatment start) were also excluded. Third, the analyses were restricted to patients starting treatment in 2016 or later (secukinumab was first available 2015), on the assumption that patients starting a newly introduced drug may differ from patients initiating drugs that have been available longer. Fourth, a Cox model was used, with inverse probability treatment weights (IPTWs), in which all covariates were included except for the number of previous b/tsDMARDs and disease duration, which were separately adjusted for, due to imbalance in the weights for these two variables.

### Post-hoc analysis

Due to the unexpectedly high absolute 1-year risk of hospitalized infections found for secukinumab compared with adalimumab, we performed a post hoc analysis to explore the possible extent of residual confounding. In this analysis, we used data only from Sweden, where we had access to information on additional potential confounders, namely length of formal education, smoking status, civil status, use of antidepressive drugs in the year prior to treatment start, as well as a longer follow-up (until 31 December 2020). Based on this data, we performed a series of Cox regression analyses comparing the hazard of hospitalized infections for secukinumab with adalimumab, gradually adjusting for additional confounders (for definitions see Supplementary Fig. S1, available at *Rheumatology* online).

### Statistical programs

Statistical analyses were performed in SAS (version 9.4) and Stata (version 16.1).

### Ethical approval

Appropriate ethical and/or data protection committees in each country approved of the study. Denmark: ethical approval is not required for registry studies (komitélovens §14, stk. 2, www.nvk.dk), Capital Region

Data-protection Office RH-2015-209, I-suite 04145; Finland: the Helsinki University Hospital coordinating Ethics Committee, 73/13/03/00/2014; Norway: Regional Ethics Committee of South Eastern Norway, 2011/1339 and 2017/243; Sweden: ethical review board Stockholm, 2015/1844-31/2). Informed written consent for the reporting of anonymized registry data for research purposes was not required according to the approval committees, apart from in Norway where such approval was required (and collected) for patients included after 2012.

### Patient and public involvement

This study emanated from an international rheumatology registry collaboration (Nordic Register Pilot), in which patients were involved, but this specific study was designed without patient participation.

## Results

A total of 13 468 patients were included, contributing 18 177 treatment courses (10 393 SpA and 7784 PsA). Patients starting secukinumab were on average older compared with patients starting TNFi, had higher baseline disease activity scores, were more frequently b/tsDMARD experienced, more often treated with corticosteroids and had a higher comorbidity burden (Table 1). Higher proportions of patients starting secukinumab had previous infections (either hospitalized infections or infections in outpatient specialized care) in the last 5 years, compared with patients starting treatment with TNFi (infliximab, in particular) (Table 1). For missingness of baseline data, see Supplementary Table S2, and for baseline characteristics of previously bio-naïve patients, see Supplementary Table S3, both available at *Rheumatology* online.

### Hospitalized infections

For SpA and PsA combined, the crude cumulative incidence curves suggested a higher risk of hospitalized infections during the first year of treatment with secukinumab compared with adalimumab (Fig. 1). The absolute first-year risk of a hospitalized infection was 3.5% (69 events) for secukinumab, compared with 1.7% (54 events) for adalimumab, with the risks of the other TNFi falling in between these values. This corresponded to a crude IR for hospitalized infections during the first year of 5.0 (3.9–6.3) per 100 patient-years for secukinumab and 2.3 (1.7–3.0) for adalimumab, with the rates for the other TNFi falling in between these two rates (Table 2). IRs were generally higher for PsA compared with SpA, but had similar patterns across the bDMARDs.

Compared with secukinumab, the fully adjusted HR for hospitalized infections was 0.58 (0.39–0.85) for adalimumab and 0.63 (0.45–0.89) for etanercept. For the other TNFi, no statistically significant differences compared with secukinumab were observed in the fully adjusted analyses (Table 2). There were differences in the magnitude of the HR comparing adalimumab with

secukinumab across the included Nordic countries, but the direction was consistent (except for Denmark), and no statistically significant heterogeneity was observed (Fig. 2).

### Sensitivity analyses

The results of the sensitivity analyses (Fig. 3) confirmed those of the main analysis, with secukinumab being associated with a higher hazard of hospitalized infections, compared with adalimumab, although statistical significance was sometimes lost. The lowest HR for the TNFi, compared with secukinumab, were found in the previously bio-naïve patients, while the difference decreased in models further accounting for additional potential confounders, including number of previous b/tsDMARD courses. The results of the comparison with the combined TNFi cohorts were in line with those of adalimumab.

### Types of infection

Analyses by type of infection (hospitalized infections and infections in outpatient specialized care) suggested similar, low, rates of pneumonia, urinary tract infection and fungal infection during treatment with secukinumab and the s.c. TNFi. For infliximab, a higher rate of pneumonia was observed compared with secukinumab, with an adjusted HR of 3.37 (1.69–6.72), as well as a lower rate of fungal infections, HR 0.42 (0.20–0.88) (Table 3). The numbers of events for herpes zoster, erysipelas and tuberculosis were too low to allow for meaningful comparisons; no registered occurrence of tuberculosis was found during treatment with secukinumab.

### Post hoc analyses

The Cox regression analysis performed on Swedish data for 2015 through 2020 included 6095 patients, contributing 1869 treatment courses with secukinumab and 5040 courses with adalimumab. Overall, 71 (3.8%) events of a first hospitalized infection were registered for secukinumab, and 99 (2.0%) for adalimumab, resulting in an IR of 4.8 (95% CI 3.8, 6.1) for secukinumab and 2.4 (2.0, 3.0) for adalimumab. The crude HR, comparing adalimumab with secukinumab, was 0.49 (95% CI 0.36, 0. 68), but adding additional covariates gradually reduced the HR to 0.80 (0.57, 1.14) in the fully adjusted model, which was very similar to the results when applying the fully adjusted model from the main analyses to this dataset (HR 0.79; 0.55–1.12) (see Supplementary Fig. S1, available at *Rheumatology* online for details).

## Discussion

In this study, including 13 468 patients with SpA and PsA from the Nordic countries, we observed a doubled absolute first-year risk of hospitalized infections among individuals initiating treatment with secukinumab compared with adalimumab, with the risk for the other four

TABLE 1 Baseline characteristics of patients starting secukinumab or a TNF-inhibitor in 2015 through 2018

| | Secukinumab | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab |
|---|---|---|---|---|---|---|
| **SpA** | | | | | | |
| *N* | 806 | 1898 | 980 | 2994 | 1170 | 2545 |
| Age, mean (S.D.), years | 47 (13) | 43 (13) | 42 (13) | 43 (14) | 42 (13) | 43 (13) |
| Sex, men *n* (%) | 372 (46) | 997 (53) | 462 (47) | 1503 (50) | 660 (56) | 1402 (55) |
| Country *n* (%) | | | | | | |
| Denmark | 147 (18) | 256 (14) | 283 (29) | 552 (18) | 216 (19) | 1253 (49) |
| Finland | 101 (13) | 241 (13) | 107 (11) | 202 (7) | 278 (24) | 124 (5) |
| Norway | 61 (8) | 31 (2) | 240 (25) | 219 (7) | 52 (4) | 229 (9) |
| Sweden | 497 (62) | 1370 (72) | 350 (36) | 2021 (68) | 624 (53) | 939 (37) |
| Number of previous of b/tsDMARDs: | | | | | | |
| None, *n* (%) | 65 (8) | 847 (45) | 400 (41) | 1674 (56) | 501 (43) | 1590 (63) |
| One, *n* (%) | 158 (20) | 628 (33) | 255 (26) | 843 (28) | 298 (26) | 509 (20) |
| Two, *n* (%) | 218 (27) | 258 (14) | 155 (16) | 274 (9) | 194 (17) | 249 (10) |
| Three, *n* (%) | 165 (21) | 97 (5) | 95 (10) | 127 (4) | 95 (8) | 112 (4) |
| Four +, *n* (%) | 200 (25) | 68 (4) | 75 (8) | 76 (3) | 82 (7) | 85 (3) |
| Disease duration, mean (S.D.) | 9.1 (9.6) | 7.1 (9.5) | 7.5 (9.8) | 6.2 (9.4) | 7.5 (9.0) | 6.3 (8.8) |
| ASDAS-CRP, mean (S.D.) | 3.4 (1.1) | 3.0 (1.1) | 3.2 (1.0) | 3.1 (1.0) | 3.2 (1.1) | 3.3 (1.1) |
| BASDAI, mean (S.D.) | 6.0 (2.4) | 5.0 (2.4) | 5.3 (2.3) | 5.4 (2.2) | 5.1 (2.5) | 5.5 (2.3) |
| Patient VAS-pain, mm, mean (S.D.) | 64 (23) | 55 (26) | 58 (24) | 59 (24) | 57 (25) | 58 (25) |
| Patient VAS-global, mm, mean (S.D.) | 66 (25) | 56 (26) | 61 (25) | 60 (24) | 56 (27) | 62 (26) |
| TJC-28, mean (S.D.) | 3 (4) | 2 (3) | 2 (4) | 2 (4) | 2 (4) | 2 (4) |
| SJC-28, mean (S.D.) | 1 (2) | 1 (2) | 1 (2) | 1 (2) | 1 (2) | 1 (1) |
| CRP, mg/l, mean (S.D.) | 13 (26) | 11 (20) | 10 (16) | 10 (16) | 12 (20) | 12 (22) |
| HAQ, mean (S.D.) | 1.1 (0.6) | 0.8 (0.6) | 1.0 (0.6) | 0.9 (0.6) | 0.9 (0.6) | 0.9 (0.6) |
| Concomitant csDMARD: | | | | | | |
| MTX, *n* (%) | 56 (10) | 73 (6) | 77 (10) | 103 (5) | 82 (11) | 265 (14) |
| SSZ, *n* (%) | 23 (4) | 50 (4) | 41 (5) | 72 (3) | 51 (7) | 115 (6) |
| Any csDMARD, *n* (%) | 75 (13) | 118 (10) | 122 (16) | 175 (8) | 129 (17) | 357 (18) |
| Oral CSs, *n* (%) | 79 (14) | 107 (9) | 57 (7) | 169 (8) | 66 (9) | 129 (7) |
| History of infection[a]: | | | | | | |
| Last 5 years, *n* (%) | 245 (30) | 462 (24) | 225 (23) | 720 (24) | 281 (24) | 515 (20) |
| Last 3 years, *n* (%) | 167 (21) | 333 (18) | 156 (16) | 511 (17) | 202 (17) | 374 (15) |
| Last 1 year, *n* (%) | 68 (8) | 146 (8) | 77 (8) | 240 (8) | 90 (8) | 161 (6) |
| Comorbidity score, *n* (%)[b] | | | | | | |
| 0 | 699 (87) | 1773 (93) | 897 (91) | 2751 (92) | 1084 (93) | 2336 (92) |
| 1 | 82 (10) | 105 (6) | 57 (6) | 199 (7) | 73 (6) | 173 (7) |
| ≥2 | 25 (3) | 20 (1) | 26 (3) | 44 (1) | 13 (1) | 36 (1) |
| **PsA** | | | | | | |
| *N* | 1142 | 1303 | 674 | 2726 | 549 | 1390 |
| Age, years, mean (S.D.) | 52 (12) | 50 (13) | 49 (12) | 50 (13) | 49 (13) | 49 (13) |
| Sex, men *n* (%) | 455 (40) | 612 (47) | 268 (40) | 1213 (45) | 250 (46) | 619 (45) |
| Country *n* (%) | | | | | | |
| Denmark | 250 (22) | 195 (15) | 186 (28) | 376 (14) | 87 (16) | 606 (44) |
| Finland | 96 (8) | 124 (10) | 57 (9) | 89 (3) | 84 (15) | 51 (4) |
| Norway | 56 (5) | 9 (1) | 142 (21) | 111 (4) | 20 (4) | 125 (9) |
| Sweden | 740 (65) | 975 (75) | 289 (43) | 2150 (79) | 358 (65) | 608 (44) |
| Number of previous of b/tsDMARDs: | | | | | | |
| None, *n* (%) | 153 (13) | 566 (43) | 268 (40) | 1707 (63) | 200 (36) | 855 (62) |
| One, *n* (%) | 272 (24) | 405 (31) | 175 (26) | 653 (24) | 145 (26) | 295 (21) |
| Two, *n* (%) | 263 (23) | 189 (15) | 101 (15) | 212 (8) | 98 (18) | 115 (8) |
| Three, *n* (%) | 204 (18) | 68 (5) | 72 (11) | 84 (3) | 55 (10) | 61 (4) |
| Four +, *n* (%) | 250 (22) | 75 (6) | 58 (9) | 70 (3) | 51 (9) | 64 (5) |
| Disease duration, mean (S.D.) | 9.5 (8.8) | 7.3 (9.0) | 8.2 (8.8) | 6.5 (7.8) | 9.2 (8.6) | 7.6 (8.2) |
| DAPSA28, mean (S.D.) | 29.7 (17.3) | 24.0 (15.1) | 26.6 (17.2) | 24.8 (14.3) | 24.4 (13.6) | 26.1 (15.8) |
| Patient VAS-pain, mm, mean (S.D.) | 64 (24) | 56 (25) | 57 (26) | 58 (24) | 59 (25) | 58 (25) |
| Patient VAS-global, mm, mean (S.D.) | 65 (23) | 57 (26) | 60 (26) | 59 (24) | 59 (25) | 62 (25) |
| SJC-28, mean (S.D.) | 3 (4) | 2 (3) | 2 (3) | 2 (3) | 2 (3) | 2 (3) |
| TJC-28, mean (S.D.) | 6 (6) | 5 (6) | 5 (5) | 5 (5) | 5 (5) | 5 (6) |

(continued)

TABLE 1 Continued

| | Secukinumab | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab |
|---|---|---|---|---|---|---|
| CRP, mg/l, mean (S.D.) | 11 (20) | 9 (14) | 12 (21) | 10 (16) | 11 (20) | 11 (20) |
| HAQ, mean (S.D.) | 1.2 (0.7) | 1.0 (0.7) | 1.1 (0.7) | 1.0 (0.6) | 1.0 (0.6) | 1.1 (0.6) |
| Concomitant csDMARD | | | | | | |
| MTX, *n* (%) | 114 (15) | 83 (10) | 147 (29) | 218 (11) | 68 (17) | 388 (36) |
| SSZ, *n* (%) | 14 (2) | 16 (2) | 28 (6) | 32 (2) | 18 (5) | 62 (6) |
| Any csDMARD, *n* (%) | 144 (18) | 114 (14) | 191 (38) | 271 (14) | 84 (22) | 463 (43) |
| Oral CSs, *n* (%) | 148 (19) | 114 (14) | 72 (14) | 251 (13) | 50 (13) | 124 (11) |
| History of infection[a]: | | | | | | |
| Last 5 years, *n* (%) | 389 (34) | 330 (25) | 170 (25) | 691 (25) | 149 (27) | 317 (23) |
| Last 3 years, *n* (%) | 280 (25) | 244 (19) | 128 (19) | 519 (19) | 99 (18) | 244 (18) |
| Last 1 year, *n* (%) | 123 (11) | 110 (8) | 66 (10) | 236 (9) | 44 (8) | 96 (7) |
| Comorbidity score, *n* (%)[b] | | | | | | |
| 0 | 938 (82) | 1150 (88) | 582 (86) | 2345 (86) | 490 (89) | 1195 (86) |
| 1 | 154 (14) | 131 (10) | 73 (11) | 315 (12) | 48 (9) | 155 (11) |
| ≥2 | 50 (4) | 22 (2) | 19 (3) | 66 (2) | 11 (2) | 40 (3) |

[a]Any registered hospitalized infection or infection in outpatient specialized care. [b]Sum of number of different comorbidities registered within 5 years of: malignancy, diabetes, chronic pulmonary disease, congestive heart disease, myocardial infarction, kidney failure, and hip/knee prosthesis. ASDAS-CRP: Ankylosing Spondylitis Disease activity Score based on C-reactive peptide; b/tsDMARDs: biologic or targeted synthetic DMARDs; csDMARD: conventional synthetic DMARD; DAPSA28: 28-joint Disease Activity index for PsA; SJC-28: swollen joint count from 0 to 28; TJC-28: tender joint count from 0 to 28; VAS-global: patient global visual analogue scale assessment of disease activity; VAS-pain: visual analogue scale of pain.



FIG. 1 Crude cumulative incidence of hospitalized infections during the first year of treatment, SpA/PsA combined

TNFi falling in between. Sensitivity analyses attempting to further accommodate treatment channelling resulted in an attenuation of the HR and loss of statistical significance, suggesting that a differential use of the drugs might explain much of the observed excess risk for secukinumab. IRs for specific types of infections revealed no significant differences for secukinumab compared with the s.c. TNFi.

TNF is involved in a complex signalling system, exerting various effects on immune responses [11], in which treatment with TNFi is well known to increase the risk of serious bacterial (as well as milder) infections [24, 25], most commonly respiratory tract infections and especially during the first 6–12 months of therapy [26, 27],

as well as causing reactivation of latent tuberculosis [12, 28]. On the other hand, IL17 is thought to be involved in upholding barrier function and mucosal protection [13], and conditions associated with IL17 malfunction may lead to chronic mucocutaneous candida infections [14]. Considering these differences, it is important to gain a better understanding not only of the relative risk of hospitalized infections, but also of specific types of infections, in order to better position secukinumab in the treatment strategy of SpA and PsA.

Several previous studies have assessed the risk of serious/hospitalized infections during treatment with TNFi in RA, with an IR ranging from 2.6 to 4.7 per 100 patient-years [10, 24, 27, 29–31] (see Supplementary Table S4, available at *Rheumatology* online). A recent comparison of risk for serious infections during TNFi treatment in RA and PsA, found an ∼35% lower risk in PsA, which may at least partly be related to differences in sex and age distribution, as well as in concomitant treatment with conventional synthetic DMARDS (csDMARDs) and corticosteroids [29]. In studies focusing on PsA, IRs for serious infections of around 2.2 and 2.4 per 100 patient-years during TNFi treatment have been reported [21, 29]. These rates correspond well with the IRs for TNFi identified in the present study, and minor differences could be explained by different length of follow-up and distribution of type of TNFi.

In two previous observational studies (Li *et al.* [21] and Jin *et al.* [32]) aiming to compare the risk of serious hospitalized infections during treatment with different b/tsDMARDs in patients with PsA and psoriasis, rates of infections on IL17i (combined) and secukinumab (specifically) were reported at 2.1 and 1.2 or 1.6 per 100 patient-years (two different data sources were

**TABLE 2** Risk, incidence rates and hazard ratios of hospitalized infections

| | Secukinumab | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab |
|---|---|---|---|---|---|---|
| **SpA and PsA combined** | | | | | | |
| N | 1948 | 3201 | 1654 | 5720 | 1719 | 3935 |
| Events, N (%=absolute risk)[a] | 69 (3.5%) | 54 (1.7%) | 46 (2.8%) | 105 (1.8%) | 38 (2.2%) | 123 (3.1%) |
| Person-years | 1380 | 2340 | 1230 | 4150 | 1390 | 2950 |
| IR per 100 person-years (95% CI) | 5.0 (3.9, 6.3) | 2.3 (1.7, 3.0) | 3.7 (2.7,5.0) | 2.5 (2.1, 3.1) | 2.7 (1.9, 3.8) | 4.2 (3.5, 5.0) |
| HR, basic model (95% CI)[b] | Reference | 0.46 (0.32, 0.66) | 0.72 (0.48, 1.08) | 0.51 (0.38, 0.70) | 0.54 (0.35, 0.82) | 0.84 (0.61, 1.15) |
| HR, fully adjusted (95% CI)[c] | Reference | 0.58 (0.39, 0.85) | 0.88 (0.57, 1.37) | 0.63 (0.45, 0.89) | 0.67 (0.43, 1.02) | 1.02 (0.72, 1.44) |
| **SpA** | | | | | | |
| N | 806 | 1898 | 980 | 2994 | 1170 | 2545 |
| Events, N (%=absolute risk)[a] | 23 (2.9%) | 31 (1.6%) | 25 (2.6%) | 53 (1.8%) | 27 (2.3%) | 82 (3.2%) |
| Person-years | 560 | 1400 | 730 | 2170 | 960 | 1920 |
| IR per 100 person-years (95% CI) | 4.1 (2.6, 6.1) | 2.2 (1.5, 3.1) | 3.4 (2.2, 5.0) | 2.4 (1.8, 3.2) | 2.8 (1.9, 4.1) | 4.3 (3.4, 5.3) |
| HR, basic model (95% CI)[b] | Reference | 0.50 (0.29, 0.87) | 0.74 (0.41, 1.33) | 0.59 (0.36, 0.96) | 0.62 (0.35, 1.09) | 0.99 (0.62, 1.58) |
| HR, fully adjusted (95% CI)[c] | Reference | 0.69 (0.40, 1.21) | 0.90 (0.48, 1.69) | 0.79 (0.47, 1.32) | 0.84 (0.46, 1.51) | 1.36 (0.82, 2.27) |
| **PsA** | | | | | | |
| N | 1142 | 1303 | 674 | 2726 | 549 | 1390 |
| Events, N (%=absolute risk)[a] | 46 (4.0%) | 23 (1.8%) | 21 (3.1%) | 52 (1.9%) | 11 (2.0%) | 41 (3.0%) |
| Person-years | 820 | 940 | 500 | 1980 | 430 | 1030 |
| IR per 100 person-years (95% CI) | 5.6 (4.1, 7.5) | 2.5 (1.6, 3.7) | 4.2 (2.6, 6.4) | 2.6 (2.0, 3.4) | 2.5 (1.3, 4.6) | 4.0 (2.8, 5.4) |
| HR, basic model (95% CI)[b] | Reference | 0.45 (0.27, 0.77) | 0.77 (0.44, 1.35) | 0.47 (0.31, 0.71) | 0.46 (0.22, 0.96) | 0.72 (0.46, 1.13) |
| HR, fully adjusted (95% CI)[c] | Reference | 0.59 (0.34, 1.03) | 1.07 (0.60, 1.92) | 0.59 (0.37, 0.93) | 0.57 (0.28, 1.20) | 0.88 (0.54, 1.42) |

Combined analyses and stratified analyses for SpA and PsA during the first year of treatment. [a]Number (%) of SpA and PsA patients with a hospitalized infection during follow-up. [b]Basic model adjusted for age and sex. [c]Fully adjusted model adjusted for sex, country and baseline: age, number of previous b/tsDMARDs, duration of the disease, history of infection in the last 5 years, comorbidity score (see Methods), concomitant csDMARD and CSs, global health score, HAQ, pain score, number of swollen and tender joint counts (0–28). In the combined analyses, disease type (SpA/PsA) was also adjusted for. b/tsDMARDs: biologic or targeted synthetic DMARDs; csDMARD: conventional synthetic DMARD; HR: hazard ratio; IR: incidence rate.

Fig. 2 Meta-analysis assessing heterogeneity of the hospitalized infections across the included countries



Adjusted hazard ratio for hospitalized infections, comparing adalimumab with secukinumab (reference), SpA and PsA combined.

used in the study by Jin et al.), respectively. Both studies were based on a large number of patients, with extensive data on potential confounders, identified in insurance claims databases in the USA. In the first, Li *et al.* compared hospitalized infections in patients with PsA and psoriasis, treated with TNFi, IL17i and ustekinumab. In that study, the authors found no significant difference in risk comparing IL17i and TNFi, but a lower risk for ustekinumab [21]. A possible explanation for the differences compared with our results may be that combining the different TNFi types could cancel out within-class differences in infection risk. In the second study, Jin et al. similarly compared risks of hospitalized infections in patients with PsA and psoriasis, including the same treatments and also apremilast. Using ustekinumab as the comparator, the authors reported a higher risk for TNFi, IL17i and apremilast, and although no direct comparison of TNFi *vs* IL17i was performed, the rates were similar [32]. To understand the diverging results between these two studies and our study, differences in crude infection rates across cohorts/studies are of interest. In the study by Li *et al.*, the IRs of infections for IL17i *vs* TNFi were 2.1 *vs* 2.4, and in the study by Jin et al. for secukinumab *vs* adalimumab they were 1.23–1.61 *vs* 1.19–1.51, while in our study the IRs of adalimumab *vs* secukinumab were 2.3 *vs* 5.0. The similar IR for adalimumab/TNFi in our study and the previous studies, but the considerably higher IR for secukinumab, could suggest that secukinumab and TNFi are used differently in the USA from how it is used in the Nordic countries, or that thresholds and approaches towards when to hospitalize an infection differ.

Given our unexpectedly high rates of infections for secukinumab [18], we performed an additional post hoc analysis including only Swedish data. In this analysis, we had immediate access to a longer follow-up, and more extensive information on socio-economics and other potential confounders. The selection of confounders was partly based on a recent study developing a prediction model for serious infections during treatment with bDMARDs [33]. Gradually adding more confounders reduced the excess risk to 20% (not statistically significant).

Some limitations should be acknowledged. First, all comparisons of treatment outcomes in observational studies suffer from risk of confounding by indication. As expected, the patients treated with secukinumab were more biologic-experienced and older, but also had higher DASs and a higher frequency of prior infections (perhaps due to previously being treated with TNFi). Despite our efforts to accommodate and adjust for confounding by indication, some residual confounding is likely to remain. Second, although including a large number of patients, some of the stratified analyses were not powered to detect rare outcomes. In particular, the analyses stratified by type of infection were limited by few events. Further, in the analyses stratified by type of infection only, patients registered with an infection at hospital discharge or at a visit in specialized outpatient care were detected, and thus many milder cases would not be recorded (e.g. fungal infections or upper respiratory infections treated in primary care [34, 35]). Unfortunately, antibiotic prescription data was not available for the current study. Furthermore, smoking status, which may affect risk of infections, was not available in the combined Nordic data, but did not affect the results in the post hoc Swedish analyses. This may imply that smoking is

Fɪɢ. 3 Sensitivity analyses and hazard ratios of first hospitalized infection, with secukinumab as reference



| | | Hazard ratio |
|---|---|---|
| **adalimumab** | Main analysis | 0.58 (0.39–0.85) |
| | Including only 1st line | 0.39 (0.18–0.87) |
| | Excluding 1st line and infection 5 yrs | 0.58 (0.33–1.04) |
| | Excluding 2015 | 0.57 (0.36–0.89) |
| | IPTW | 0.77 (0.50–1.17) |
| **etanercept** | Main analysis | 0.63 (0.45–0.89) |
| | Including only 1st line | 0.40 (0.20–0.81) |
| | Excluding 1st line and infection 5 yrs | 0.86 (0.53–1.41) |
| | Excluding 2015 | 0.71 (0.49–1.02) |
| | IPTW | 0.79 (0.54–1.15) |
| **infliximab** | Main analysis | 1.02 (0.72–1.44) |
| | Including only 1st line | 0.72 (0.36–1.44) |
| | Excluding 1st line and infection 5 yrs | 1.09 (0.60–1.96) |
| | Excluding 2015 | 1.16 (0.79–1.69) |
| | IPTW | 1.25 (0.85–1.85) |
| **golimumab** | Main analysis | 0.67 (0.43–1.02) |
| | Including only 1st line | 0.52 (0.22–1.24) |
| | Excluding 1st line and infection 5 yrs | 0.52 (0.26–1.02) |
| | Excluding 2015 | 0.58 (0.32–1.02) |
| | IPTW | 0.76 (0.47–1.22) |
| **certolizumab pegol** | Main analysis | 0.88 (0.57–1.37) |
| | Including only 1st line | 0.40 (0.16–1.02) |
| | Excluding 1st line and infection 5 yrs | 0.98 (0.53–1.81) |
| | Excluding 2015 | 1.08 (0.66–1.76) |
| | IPTW | 1.05 (0.66–1.67) |
| **All TNFis** | Main analysis | 0.72 (0.54–0.97) |
| | Including only 1st line | 0.50 (0.25–0.98) |
| | Excluding 1st line and infection 5 yrs | 0.80 (0.52–1.24) |
| | Excluding 2015 | 0.79 (0.58–1.08) |
| | IPTW | 0.91 (0.65–1.27) |

Including the first year of treatment for SpA and PsA combined, using the same fully adjusted model as in the main analyses (except for analysis 4 = IPTW). Results shown for each of the TNFi and for all TNFi combined. Sensitivity analyses: 1. Previously bio-naïve patients. 2. Restricted to patients starting a ≥2nd b/tsDMARD treatment course and excluding patients with previous infection within 5 years prior to treatments start. 3. Only including treatment starts from 2016 or later. 4. Cox model with an IPTW-adjusted analysis. b/tsDMARD, biologic/targeted synthetic DMARD; IPTW, inverse probability treatment weighted; TNFi, TNF inhibitors.

not acting as a confounder with regard to type of treatment.

In this large observational study, we conclude that in the Nordic countries there is a low frequency of hospitalized infections during treatment with secukinumab or TNFi in SpA and PsA. In clinical practice, secukinumab was mainly used in bDMARD-experienced patients, and the doubled absolute risk in patients treated with secukinumab, compared with adalimumab (with the other TNFi falling in between) seemed to be partly or entirely explained by confounding factors.

## Acknowledgements

**TABLE 3** Incidence rates and hazard ratios for different types of infections

| | Secukinumab | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab |
|---|---|---|---|---|---|---|
| **Pneumonia** | | | | | | |
| N | 1948 | 3201 | 1654 | 5720 | 1719 | 3935 |
| Events, N (%=absolute risk)[a] | 12 (0.6%) | 12 (0.4%) | 14 (0.9%) | 32 (0.6%) | 8 (0.5%) | 54 (1.4%) |
| Person-years | 1410 | 2350 | 1250 | 4180 | 1400 | 2990 |
| IR per 100 person-years (95% CI) | 0.9 (0.4, 1.5) | 0.5 (0.3, 0.9) | 1.1 (0.6, 1.9) | 0.8 (0.5, 1.1) | – | 1.8 (1.4, 2.4) |
| HR, basic model (95% CI)[b] | Reference | 0.66 (0.29, 1.52) | 1.46 (0.64, 3.33) | 0.97 (0.50, 1.89) | – | 2.32 (1.21, 4.46) |
| HR, fully adjusted[c] | Reference | 1.03 (0.45, 2.39) | 2.03 (0.88, 4.67) | 1.56 (0.79, 3.08) | – | 3.37 (1.69, 6.72) |
| **Urinary tract infections** | | | | | | |
| N | 1948 | 3201 | 1654 | 5720 | 1719 | 3935 |
| Events, N (%=absolute risk)[a] | 23 (1.2%) | 22 (0.7%) | 16 (1.0%) | 42 (0.7%) | 15 (0.9%) | 36 (0.9%) |
| Person-years | 1400 | 2350 | 1250 | 4180 | 1400 | 2990 |
| IR per 100 person-years (95% CI) | 1.6 (1.0, 2.5) | 0.9 (0.6, 1.4) | 1.3 (0.7, 2.1) | 1.0 (0.7, 1.4) | 1.1 (0.6, 1.8) | 1.2 (0.8, 1.7) |
| HR, basic model (95% CI)[b] | Reference | 0.70 (0.38, 1.28) | 0.98 (0.49, 1.96) | 0.71 (0.42, 1.19) | 0.89 (0.45, 1.76) | 0.92 (0.53, 1.60) |
| HR, fully adjusted[c] | Reference | 0.80 (0.43, 1.50) | 1.43 (0.70, 2.90) | 0.84 (0.48, 1.47) | 1.02 (0.51, 2.03) | 1.38 (0.78, 2.42) |
| **Fungal** | | | | | | |
| N | 1948 | 3201 | 1654 | 5720 | 1719 | 3935 |
| Events, N (%=absolute risk)[a] | 21 (1.1%) | 23 (0.7%) | 10 (0.6%) | 40 (0.7%) | 8 (0.5%) | 15 (0.4%) |
| Person-years | 1400 | 2350 | 1250 | 4180 | 1400 | 3000 |
| IR per 100 person-years (95% CI) | 1.5 (0.9, 2.3) | 1.0 (0.6, 1.5) | 0.8 (0.4, 1.5) | 1.0 (0.7, 1.3) | – | 0.5 (0.3, 0.8) |
| HR, basic model (95% CI)[b] | Reference | 0.66 (0.36, 1.20) | 0.50 (0.23, 1.10) | 0.64 (0.37, 1.10) | – | 0.35 (0.17, 0.69) |
| HR, fully adjusted[c] | Reference | 0.64 (0.34, 1.22) | 0.62 (0.27, 1.44) | 0.60 (0.33, 1.09) | – | 0.42 (0.20, 0.88) |
| **Erysipelas** | | | | | | |
| N | 1948 | 3201 | 1654 | 5720 | 1719 | 3935 |
| Events, N (%=absolute risk)[a] | 11 (0.6%) | 6 (0.2%) | 7 (0.4%) | 19 (0.3%) | 6 (0.4%) | 7 (0.2%) |
| Person/years | 1410 | 2350 | 1250 | 4190 | 1400 | 3000 |
| IR per 100 person-years (95% CI) | 0.8 (0.4, 1.4) | – | – | 0.5 (0.3, 0.7) | – | – |
| **Zoster** | | | | | | |
| N | 1948 | 3201 | 1654 | 5720 | 1719 | 3935 |
| Events, N (%=absolute risk)[a] | 4 (0.2%) | 2 (0.1%) | 0 (0.0%) | 4 (0.1%) | 1 (0.1%) | 4 (0.1%) |
| Person-years | 1410 | 2360 | 1250 | 4190 | 1410 | 3000 |
| **Tuberculosis** | | | | | | |
| N | 1948 | 3201 | 1654 | 5720 | 1719 | 3935 |
| Events, N (%=absolute risk)[a] | 0 (0.0%) | 1 (0.0%) | 1 (0.1%) | 1 (0.0%) | 2 (0.1%) | 3 (0.1%) |
| Person-years | 1410 | 2360 | 1250 | 4190 | 1410 | 3000 |

Results are presented combined for PsA and SpA and including both hospitalized infections and infections in outpatient specialized care, during the first year of treatment. Since the numbers of infection events only include the prespecified types of infections and include outpatient care, they are not directly comparable with the number of events in the main analysis. [a]Number (%) of patients with an infection during follow-up. [b]Basic model adjusted for age and sex. [c]Fully adjusted model adjusted for age, sex, disease type (SpA/PsA), number of previous b/tsDMARDs, duration of the disease, history of infection in the last 5 years, comorbidity score (see Methods), concomitant csDMARD and CSs, global health score, HAQ, pain score, number of swollen and tender joint counts (0–28). Country was added as strata. b/tsDMARDs: biologic or targeted synthetic DMARDs; csDMARD: conventional synthetic DMARD; HR: hazard ratio; IR: incidence rate.

## Data availability statement

The data underlying this article will be shared on reasonable request to the corresponding author.

## Supplementary data

Supplementary data are available at *Rheumatology* online.

## References

1   Gossec L, Baraliakos X, Kerschbaumer A *et al.* EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700–12.

2   Singh JA, Guyatt G, Ogdie A *et al.* Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 2019;71:5–32.

3   Ward MM, Deodhar A, Gensler LS *et al.* 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res 2019;71:1285–99.

4   van der Heijde D, Ramiro S, Landewe R *et al.* 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76: 978–91.

5   Lindstrom U, Glintborg B, Di Giuseppe D *et al.* Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology (Oxford) 2021;60: 3635–45.

6   Glintborg B, Lindstrom U, Di Giuseppe D *et al.* One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in spondyloarthritis: results from five Nordic biologic registries including more than 10,000 treatment courses. Arthritis Care Res (Hoboken) 2022;74: 748–58.

7   McInnes IB, Behrens F, Mease PJ *et al.* Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020;395: 1496–505.

8   Mease PJ, Smolen JS, Behrens F *et al.* A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 2020;79: 123–31.

9   Gron KL, Arkema EV, Glintborg B *et al.* Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis 2019;78:320–7.

10  Pawar A, Desai RJ, Solomon DH *et al.* Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis 2019;78:456–64.

11  Gough P, Myles IA. Tumor necrosis factor receptors: pleiotropic signaling complexes and their differential effects. Front Immunol 2020;11:585880.

12  Keane J, Gershon S, Wise RP *et al.* Tuberculosis associated with infliximab, a tumor necrosis factor alpha–neutralizing agent. N Engl J Med 2001;345:1098–104.

13  Stockinger B, Omenetti S. The dichotomous nature of T helper 17 cells. Nat Rev Immunol 2017;17:535–44.

14  Puel A. Human inborn errors of immunity underlying superficial or invasive candidiasis. Hum Genet 2020;139: 1011–22.

15  Langley RG, Elewski BE, Lebwohl M *et al.* Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 2014;371:326–38.

16  Griffiths CE, Reich K, Lebwohl M *et al.* Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;386: 541–51.

17  Deodhar A, Mease PJ, McInnes IB *et al.* Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 2019;21:111.

18  Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517–24.

19  Aaltonen KJ, Ylikyla S, Tuulikki Joensuu J *et al.* Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford) 2017;56:725–35.

20 Runarsdottir EE, Gunnarsdottir AI, Love TJ, Gunnarsson PS, Gudbjornsson B; ICEBIO. The majority of patients with psoriatic arthritis are not eligible for randomised clinical trials. Clin Exp Rheumatol 2018;36:1068–73.

21 Li X, Andersen KM, Chang HY, Curtis JR, Alexander GC. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis 2020;79:285–91.

22 Glintborg B, Lindstrom U, Aaltonen K *et al.* Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries. Scand J Rheumatol 2018;47:465–74.

23 Chatzidionysiou K, Hetland ML, Frisell T *et al.* Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. RMD Open 2018;4:e000655.

24 Curtis JR, Patkar N, Xie A *et al.* Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125–33.

25 Modesti V, Ramonda R, Ortolan A *et al.* Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol 2012;41:490–1.

26 Askling J, Fored CM, Brandt L *et al.* Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339–44.

27 Galloway JB, Hyrich KL, Mercer LK *et al.* Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124–31.

28 Ramiro S, Sepriano A, Chatzidionysiou K *et al.* Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1101–36.

29 Christensen IE, Lillegraven S, Mielnik P *et al.* Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study. Ann Rheum Dis 2022;81:398–401.

30 Ozen G, Pedro S, England BR *et al.* Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs. ACR Open Rheumatol 2019;1(7):424–32.

31 van Dartel SA, Fransen J, Kievit W *et al.* Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013;72:895–900.

32 Jin Y, Lee H, Lee MP *et al.* Risk of hospitalized serious infection after initiating ustekinumab or other biologics for psoriasis or psoriatic arthritis. Arthritis Care Res 2021; Advance Access published 10 May 2021, doi: 10.1002/acr.24630

33 Krabbe S, Gron KL, Glintborg B *et al.* Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model. Rheumatology (Oxford) 2021;60:3834–44.

34 Alonso S, Villa I, Fernández S *et al.* Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: secukinumab in cantabria and ASTURias study. Front Med 2021;8:679009.

35 Ramonda R, Lorenzin M, Carriero A *et al.* Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open 2021;7:e001519.